DRRX has been in the news 900% more than usual
Sep 04, 2024, 10:31 PM
-18.24%
What does DRRX do
DURECT, based in Cupertino, California, develops investigational therapies, including Larsucosterol for alcohol-associated hepatitis. Its FDA-approved products include POSIMIR and PERSERIS, while employing 48 staff since its 2000 IPO.
DRRX has been in the news recently: DURECT Corporation will participate in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, where it will discuss its epigenetic therapies for serious conditions. This participation highlights DURECT's commitment to advancing innovative treatments in the biotech field.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.